What exactly did UBS do to Sempra on March 06, 2026?

UBS maintained a Neutral rating on Sempra on March 06, 2026 and raised the price target to $100. The firm kept its stance but adjusted valuation expectations based on Oncor prospects.

How should I read the SRE analyst rating in portfolio terms?

A Neutral SRE analyst rating means neither a buy nor sell bias. It suggests holding existing exposure and watching regulatory updates and Oncor developments before changing position size.

Does the new price target imply upside for SRE?

The raised SRE price target to $100 implies modest upside versus current trading levels. UBS expects improved valuation drivers but not a strong re-rating at this time.

How does Meyka AI view the UBS note on Sempra?

Meyka AI views the UBS action as a valuation refinement and rates SRE **B+**. We factor analyst consensus, sector performance, and key metrics into our grade for context.

Analyst Ratings

UBS Maintains Neutral on Sempra (SRE) Mar 2026, PT Raised to $100

ByDanny Kontos March 9, 2026

On March 06, 2026 UBS kept its rating at Neutral on Sempra (SRE) while raising the price target to $100. The SRE analyst rating update signals steady conviction in the utility’s outlook tied to its Oncor prospects. UBS left the stance unchanged, but the higher target gives investors a clearer valuation anchor amid recent volatility. The rating move coincided with a short-term stock pullback of -1.41% ($-1.32), reflecting market sensitivity to analyst nuance and near-term cash flow expectations.